← Back to Search
Actively Targeted Nanomedicines For Precision Cancer Therapy: Concept, Construction, Challenges And Clinical Translation.
Wenxing Gu, F. Meng, Rainer Haag, Z. Zhong
Published 2020 · Medicine
Download PDFAnalyze on Scholarcy
The development of targeted nanomedicines for cancer therapy has been an utmost focus of research across different fields including materials science, nanotechnology, biotechnology, pharmaceutics, and clinical medicine. Vehicle-mediated, enhanced and tumor-selective delivery is deemed as a powerful tool to boost the efficacy and meanwhile minimize the off-target effect of potent chemo drugs, and to potentiate biopharmaceuticals such as nucleic acids (DNA, siRNA, miRNA, mRNA, CRISPR/Cas9, etc.), proteins and peptides that poorly penetrate the cell membrane on their own while having explicit effects intracellularly. The targeted nanomedicines may further provide imminent treatments for intractable brain tumors by transporting drugs across the blood-brain barriers, multi-drug resistant (MDR) tumors by evading the MDR pathways, metastatic tumors by inhibiting migratory tumor cells, and relapsed tumors by eliminating the cancer stem cells. The preclinical and clinical investigations demonstrate the clear benefits of targeted nanomedicines in treating advanced solid and hematological malignancies. In this review, we highlight the design and construction of conceptually interesting and clinically viable actively targeted cancer nanomedicines containing small molecular drugs, nucleic acid drugs, or protein/peptide drugs, discuss their pros and cons, and give perspectives on the future developments and clinical translation. We are convinced that with collaborative research and development across the disciplines, actively targeted cancer nanomedicines will make a breakthrough and become an indispensable platform for precision cancer therapy.
This paper references
Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy.
L. Liu (2017)
Polymer Vesicles: Modular Platforms for Cancer Theranostics.
Fangyingkai Wang (2018)
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Joseph G. Reynolds (2012)
Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Y. Zou (2016)
The highly efficient delivery of exogenous proteins into cells mediated by biodegradable chimaeric polymersomes.
G. Liu (2010)
Nanomedicine‐based combination anticancer therapy between nucleic acids and small‐molecular drugs☆
W. Huang (2017)
Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma.
Y. Jiang (2018)
The mannose receptor
L. Martínez-Pomares (2012)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
P. Hamann (2002)
EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Yuan Fang (2017)
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
H. Burris (2011)
On the cellular processing of non-viral nanomedicines for nucleic acid delivery: mechanisms and methods.
D. Vercauteren (2012)
Doxil®--the first FDA-approved nano-drug: lessons learned.
Y. Barenholz (2012)
Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA.
Federico Perche (2011)
Saporin‐loaded CD44 and EGFR dual‐targeted nanogels for potent inhibition of metastatic breast cancer in vivo
J. Chen (2019)
Actively-targeted polyion complex micelles stabilized by cholesterol and disulfide cross-linking for systemic delivery of siRNA to solid tumors.
Yusuke Oe (2014)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. Connors (2018)
Ligand-targeted liposome design: challenges and fundamental considerations.
Gavin T Noble (2014)
Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination.
D. Zhu (2019)
GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Y. Zou (2018)
Pegylated Liposomal Doxorubicin
S. Duggan (2012)
Therapeutic antibodies: Magic bullets hit the target
T. Gura (2002)
FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer
Esteban A. Orellana (2017)
Progress and challenges towards targeted delivery of cancer therapeutics
D. Rosenblum (2018)
Therapeutic opportunities for targeted liposomal drug delivery
T. Allen (1996)
Hyaluronan–CD44 interactions as potential targets for cancer therapy
S. Misra (2011)
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma.
Chao Liang (2017)
Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek (2017)
Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery
Hyukjin Lee (2012)
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
Yu Zhou (2007)
Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.
A. Wicki (2015)
Polymersomes: tough vesicles made from diblock copolymers.
B. Discher (1999)
Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
D. W. Laske (1997)
Antibody–drug conjugates for cancer
C. Chau (2019)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
D. Goldenberg (2015)
Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner
S. Hosokawa (2003)
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy.
M. Talelli (2013)
Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.
C. Esposito (2014)
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Jeffrey Hrkach (2012)
Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells
C. Mamot (2012)
mRNA Polyplexes with Post-Conjugated GALA Peptides Efficiently Target, Transfect, and Activate Antigen Presenting Cells
B. Lou (2019)
Precise engineering of siRNA delivery vehicles to tumors using polyion complexes and gold nanoparticles.
H. Kim (2014)
Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo
J. Heidel (2007)
Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent
J. Hopewell (2001)
Regulation of iron transport and the role of transferrin.
Konstantinos Gkouvatsos (2012)
Clinical Translation of Nanomedicine.
Y. Min (2015)
CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice.
Yinan Zhong (2020)
Targeting of drugs
G. Gregoriadis (1977)
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
Hyunbo Shim (2020)
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
C. Mamot (2005)
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
I. Krop (2010)
Targeted Delivery of miRNA 155 to Tumor Associated Macrophages for Tumor Immunotherapy.
Xinlong Zang (2019)
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.
J. I. Hare (2017)
RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
P. Barata (2016)
Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond).
Ulrich Lächelt (2015)
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Gail D Lewis Phillips (2008)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
P. Thuss-Patience (2017)
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
A. Younes (2010)
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
H. Lee (2017)
Recent applications of PLGA based nanostructures in drug delivery.
Maria Mir (2017)
Cancer nanomedicine: progress, challenges and opportunities
J. Shi (2017)
Selective gene delivery in dendritic cells with mannosylated and histidylated lipopolyplexes
Federico Perche (2011)
Bioresponsive functional nanogels as an emerging platform for cancer therapy
Dechun Huang (2018)
PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications.
Keru Zhang (2014)
Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study.
T. Birngruber (2014)
Highly efficacious and specific anti‐glioma chemotherapy by tandem nanomicelles co‐functionalized with brain tumor‐targeting and cell‐penetrating peptides
Yaqin Zhu (2018)
Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.
Cuitian Chen (2017)
Tumor targeted genome editing mediated by a multi‐functional gene vector for regulating cell behaviors
Bo-Ya Liu (2018)
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin.
K. Sankhala (2009)
Granzyme B‐loaded, cell‐selective penetrating and reduction‐responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo
Weijing Yang (2018)
Lung cancer specific and reduction-responsive chimaeric polymersomes for highly efficient loading of pemetrexed and targeted suppression of lung tumor in vivo.
Weijing Yang (2018)
Protein Toxin Chaperoned by LRP-1-Targeted Virus-Mimicking Vesicles Induces High-Efficiency Glioblastoma Therapy In Vivo.
Y. Jiang (2018)
Tumor‐targeted pH/redox dual‐sensitive unimolecular nanoparticles for efficient siRNA delivery
G. Chen (2017)
&agr;v&bgr;3 Integrin‐targeted reduction‐sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo
P. Zhong (2017)
Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.
K. Pirollo (2016)
Tumor targeting via EPR: Strategies to enhance patient responses.
Susanne K Golombek (2018)
Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.
Huazhen Qin (2019)
Antibodies as carriers of anticancer agents.
R. Rubens (1974)
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization.
Qihang Sun (2017)
Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles.
Yu Yi (2016)
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
A. Starodub (2015)
Nanogels for intracellular delivery of biotherapeutics
D. Li (2017)
Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
Steven Coats (2019)
Polymer–drug conjugate therapeutics: advances, insights and prospects
Iriny Ekladious (2018)
Nanomedicine-mediated cancer stem cell therapy.
Song Shen (2016)
Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain‐targeting chimaeric polymersomes
Y. Shi (2018)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz (2019)
Bankruptcy filing worries developers of nanoparticle cancer drugs
H. Ledford (2016)
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
R. Sharkey (2015)
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.
Jinbing Xie (2019)
The current state and future directions of RNAi-based therapeutics
Ryan L. Setten (2019)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
H. Kantarjian (2016)
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.
N. Senzer (2013)
Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
Denzil Furtado (2018)
Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
H. He (2019)
Paul Ehrlich (1854-1915): man with the magic bullet.
S. Y. Tan (2010)
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
D. V. Von Hoff (2016)
Near-Infrared Photoimmunotherapy of Cancer
Hisataka Kobayashi (2019)
Tumor‐Specific Self‐Degradable Nanogels as Potential Carriers for Systemic Delivery of Anticancer Proteins
Qiuwen Zhu (2018)
Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity
J. Gubernator (2011)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
A. Bardia (2017)
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akin Akinc (2019)
Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer siRNA Therapy In Vivo.
Y. Zou (2017)
Smart cancer nanomedicine
R. van der Meel (2019)
Anisamide-Decorated pH-Sensitive Degradable Chimaeric Polymersomes Mediate Potent and Targeted Protein Delivery to Lung Cancer Cells.
L. Lu (2015)
Adaptive Polymersome and Micelle Morphologies in Anticancer Nanomedicine: From Design Rationale to Fabrication and Proof‐of‐Concept Studies
Imke A. B. Pijpers (2018)
A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers.
A. Siefker-Radtke (2016)
Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination.
Sejin Son (2020)
Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels.
Kun Liang (2016)
A Targeted and Stable Polymeric Nanoformulation Enhances Systemic Delivery of mRNA to Tumors.
Qixian Chen (2017)
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
A. Advani (2010)
Nanoparticle Orientation to Control RNA Loading and Ligand Display on Extracellular Vesicles for Cancer Regression
Fengmei Pi (2017)
Efficient Intracellular Delivery of RNase A Using DNA Origami Carriers.
Shuai Zhao (2019)
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Daniel Bobo (2016)
Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles.
Ying-Li Luo (2018)
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.
C. Espelin (2016)
Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Yaohua Wei (2019)
Strategies and challenges for the next generation of antibody–drug conjugates
A. Beck (2017)
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial
K. Autio (2018)
Antibody‐drug conjugates‐ stability and formulation
C. Dürr (2019)
pH-Sensitive Coiled-Coil Peptide-Cross-Linked Hyaluronic Acid Nanogels: Synthesis and Targeted Intracellular Protein Delivery to CD44 Positive Cancer Cells.
L. Ding (2018)
Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery.
R. Cheng (2011)
Lipopepsomes: A novel and robust family of nano‐vesicles capable of highly efficient encapsulation and tumor‐targeted delivery of doxorubicin hydrochloride in vivo
M. Qiu (2018)
PECAM‐1 directed re‐targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E‐mediated uptake
H. Parhiz (2018)
Trastuzumab emtansine for HER2-positive advanced breast cancer.
S. Verma (2012)
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
N. Bertrand (2014)
Mylotarg: antibody-targeted chemotherapy comes of age
E. Sievers (2001)
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.
D. Stirland (2013)
CD44, a therapeutic target for metastasising tumours.
V. Orian-Rousseau (2010)
Cell-Type-Specific CRISPR/Cas9 Delivery by Biomimetic Metal Organic Frameworks.
M. Alyami (2020)
miRNA nanotherapeutics for cancer.
Aditya Ganju (2017)
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
Y. Matsumura (2004)
Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
A. Bardia (2019)
Protein Nanotherapeutics as an Emerging Modality for Cancer Therapy
Liang Cheng (2018)
Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules
M. Mitsunaga (2011)
Non-viral gene delivery via membrane-penetrating, mannose-targeting supramolecular self-assembled nanocomplexes.
Lichen Yin (2013)
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
A. Ocean (2017)
PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery
Y. Zhao (2016)
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
R. Heist (2017)
Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma
P. J. Gaillard (2014)
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
R. A. de Claro (2012)
Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo.
Yaohua Wei (2020)
Folate receptor-directed orthogonal click-functionalization of siRNA lipopolyplexes for tumor cell killing in vivo.
P. M. Klein (2018)
Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Yinan Zhong (2015)
Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
M. Birrer (2019)
The transferrin receptor and the targeted delivery of therapeutic agents against cancer.
T. R. Daniels (2012)
Selective Cell Penetrating Peptide‐Functionalized Polymersomes Mediate Efficient and Targeted Delivery of Methotrexate Disodium to Human Lung Cancer In Vivo
Weijing Yang (2018)
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
K. Miller (2016)
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
L. Xu (2002)
The dawning era of polymer therapeutics
R. Duncan (2003)
Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies.
Arman Jahangiri (2017)
Chemical modifications of nucleic acid drugs and their delivery systems for gene‐based therapy
Changmai Chen (2018)
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
L. Seymour (2002)
Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
X. Wei (2015)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
K. Tsuchikama (2016)
Polymersome delivery of siRNA and antisense oligonucleotides.
Y. Kim (2009)
A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival
Sang-soo Kim (2014)
Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer.
M. Li (2019)
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
P. Munster (2018)
Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer.
M. Perepelyuk (2018)
Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope
L. Salvioni (2019)
FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Emily Y. Jen (2018)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
M. Davis (2010)
To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
F. Danhier (2016)
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
C. Mamot (2012)
mRNA vaccines — a new era in vaccinology
N. Pardi (2018)
CRISPR/Cas9 for cancer research and therapy.
T. Zhan (2019)
Customizing poly(lactic-co-glycolic acid) particles for biomedical applications.
E. Swider (2018)
Peptide‐decorated polymeric nanomedicines for precision cancer therapy
H. Sun (2018)
HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor.
L. Ding (2019)
Selective Cell Penetrating Peptide-Functionalized Envelope-Type Chimeric Lipopepsomes Boost Systemic RNAi Therapy for Lung Tumors.
M. Qiu (2019)
Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug.
S. A. Costa (2019)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams (2018)
Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
Hongran Yin (2019)
Promises and Pitfalls of Intracellular Delivery of Proteins
Ailing Fu (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Márk Barok (2014)
CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma.
Wen-Xing Gu (2019)
Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)
P. Gaillard (2014)
Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Yinan Zhong (2016)
Development of "CLAN" Nanomedicine for Nucleic Acid Therapeutics.
Cong-Fei Xu (2019)
The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.
M. Davis (2009)
Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy
Kazuhide Sato (2018)
Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy
Lingmin Zhang (2017)
Recent progress in development of siRNA delivery vehicles for cancer therapy.
H. Kim (2016)
Small-Sized and Robust Chimaeric Lipopepsomes: A Simple and Functional Platform with High Protein Loading for Targeted Intracellular Delivery of Protein Toxin in Vivo
M. Qiu (2018)
Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin
Y. Zou (2018)
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
Jonathan E Zuckerman (2014)
CD44 Receptor Targeting and Endosomal pH-Sensitive Dual Functional Hyaluronic Acid Micelles for Intracellular Paclitaxel Delivery.
Y. Liu (2016)
Brentuximab Vedotin (SGN-35)
J. Katz (2011)
Bioresponsive Chimaeric Nanopolymersomes Enable Targeted and Efficacious Protein Therapy for Human Lung Cancers in Vivo
Weijing Yang (2017)
Cancer‐derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism‐dependent targeting
S. Kim (2017)
Targeted therapy using nanotechnology: focus on cancer
V. Sanna (2014)
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm (2016)
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
D. Bartlett (2007)
Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells
A. Le Moignic (2018)
Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes.
X. Li (2015)
ATN-161 Peptide Functionalized Reversibly Cross-Linked Polymersomes Mediate Targeted Doxorubicin Delivery into Melanoma-Bearing C57BL/6 Mice.
N. Zhang (2017)
Ligand-Installed Nanocarriers toward Precision Therapy.
P. Mi (2019)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
T. Cardillo (2015)
CD44 targeting biocompatible and biodegradable hyaluronic acid cross‐linked zein nanogels for curcumin delivery to cancer cells: In vitro and in vivo evaluation
Hae-yong Seok (2018)
Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface.
T. Heath (1980)
mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.
Y. Wang (2018)
Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics.
M. Ashrafizadeh (2019)
Glucose‐linked sub‐50‐nm unimer polyion complex‐assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1‐overexpressing breast cancer stem‐like cells
Yu Yi (2019)
Small, Traceable, Endosome-Disrupting, and Bioresponsive Click Nanogels Fabricated via Microfluidics for CD44-Targeted Cytoplasmic Delivery of Therapeutic Proteins.
K. Huang (2019)
Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Janet L Markman (2013)
Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness
Ángela Molina-Crespo (2019)
Polymersomes for therapeutic delivery of protein and nucleic acid macromolecules: From design to therapeutic applications.
S. Iqbal (2020)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
B. Li (2018)
Insights into maleimide‐thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting
Lucía Martínez-Jothar (2018)
Polymer therapeutics: concepts and applications.
R. Haag (2006)
Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors.
A. Iyer (2014)
Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping.
Z. Zheng (2019)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
P. Senter (2012)
Dually Gated Polymersomes for Gene Delivery.
Fangyingkai Wang (2018)
EGFR and CD44 Dual-Targeted Multifunctional Hyaluronic Acid Nanogels Boost Protein Delivery to Ovarian and Breast Cancers In Vitro and In Vivo.
J. Chen (2017)
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.
P. Julyan (1999)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
H. Kantarjian (2012)
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
S. Mitragotri (2014)
Dual-targeted nanomedicines for enhanced tumor treatment
Y. Zhu (2018)
Design concepts of polyplex micelles for in vivo therapeutic delivery of plasmid DNA and messenger RNA.
S. Uchida (2019)
How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation
J. Ioannidis (2018)
Tools for translation: non-viral materials for therapeutic mRNA delivery
Khalid A Hajj (2017)
Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide
H. Wang (2018)
Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas
M. Weaver (2004)
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
R. Suzuki (2008)
Abstract CT155: Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)
J. Gray (2017)
Polymer therapeutics: clinical applications and challenges for development.
M. Vicent (2009)
Multifunctional Click Hyaluronic Acid Nanogels for Targeted Protein Delivery and Effective Cancer Treatment in Vivo
J. Chen (2016)